7 completed, 5 terminated, 3 active not recruiting, 3 recruiting. 21 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 7, Terminated 5, Active not recruiting 3, Recruiting 3, Suspended 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 4, Terminated 2, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Acute Lymphoblastic Leukemia (ALL): new trials by email Literature Review of Acute Lymphoblastic Leukemia (ALL) trials Research Report on Acute Lymphoblastic Leukemia (ALL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Idasanutlin, Venetoclax, Cyclophosphamide - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 38 | 2020-01-27 | 2024-12-20 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Cyclophosphamide, Fludarabine, Thiotepa - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 69 | 2019-01-31 | 2026-09-15 |
| International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Bortezomib - Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Recruiting | Charite University, Berlin, Germany | 250 | 2017-09-01 | 2026-03-17 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 170 | 2016-07-14 | 2025-08-12 |
| Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Moxetumomab Pasudotox - Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Terminated | Center for International Blood and Marrow Transplant Research | 1 | 2015-05-01 | 2015-09-16 |
| Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment CPX-351 - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2015-04-01 | 2018-03-14 | |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Cyclophosphamide, Fludarabine, G-CSF - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | St. Jude Children's Research Hospital | 12 | 2014-10-01 | 2017-05-30 |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs CDX-301, CDX-301 and plerixafor - For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | Phase 2 | Terminated | Celldex Therapeutics | 36 | 2014-07-01 | 2017-04-07 |
| An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients CPX-351 - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Completed | Jazz Pharmaceuticals | 26 | 2014-07-01 | 2017-11-30 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT ALT-803 - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 33 | 2013-11-11 | 2020-08-12 |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide - Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | Unknown | Diane George | 14 | 2013-06-03 | 2024-06-04 |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM NiCord® - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Completed | Gamida Cell ltd | 36 | 2013-04-01 | 2020-10-22 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon) - Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | Stanford University | 68 | 2012-02-09 | 2025-08-19 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies NiCord® - Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | Completed | Gamida Cell ltd | 12 | 2010-11-01 | 2021-08-03 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Regulatory T-cells, Conventional T-cells, Melphalan - Leukemia, Acute, Chronic Myelogenous Leukemia (CML) | Phase 1 / Phase 2 | Terminated | Everett Meyer | 10 | 2009-06-01 | 2018-06-27 |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia Marqibo® (vincristine sulfate liposomes injection) - Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 65 | 2007-05-01 | 2021-03-05 |
Showing 20 of 21. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (21) · Leukemia, Myeloid, Acute (16) · Myelodysplastic Syndromes (14) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Lymphoma, Non-Hodgkin (9) · Leukemia, Myelomonocytic, Juvenile (5) · Hodgkin Disease (4) · Leukemia (4) · Hematologic Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Recurrence (3) · Lymphoma (2) · Neoplasms (2) · Sarcoma, Myeloid (2) · Acquired Immunodeficiency Syndrome (1)
Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Leukemia, Lymphoid (21) · Lymphatic Diseases (21) · Lymphoproliferative Disorders (21) · Neoplasms by Histologic Type (21) · Neoplasms (19) · Leukemia (17) · Leukemia, Myeloid (16) · Bone Marrow Diseases (14) · Disease Attributes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13)
Cyclophosphamide (7) · Melphalan (5) · Thiotepa (5) · fludarabine (5) · blinatumomab (4) · fludarabine phosphate (4) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · thymoglobulin (3) · Antilymphocyte Serum (2) · CPX-351 (2) · Cytarabine (2) · Mesna (2) · Rituximab (2) · Tacrolimus (2)
St. Jude Children's Research Hospital (4) · Gamida Cell ltd (2) · Jazz Pharmaceuticals (2) · Armaceutica, Inc. (1) · Bambino Gesù Hospital and Research Institute (1) · Celldex Therapeutics (1) · Center for International Blood and Marrow Transplant Research (1) · Charite University, Berlin, Germany (1) · Dana-Farber Cancer Institute (1) · Diane George (1) · Everett Meyer (1) · Hoffmann-La Roche (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · Spectrum Pharmaceuticals, Inc (1)
United States (18) · France (3) · Italy (3) · Netherlands (3) · United Kingdom (3) · Austria (2) · Canada (2) · Czechia (2) · Denmark (2) · Finland (2) · Germany (2) · Israel (2) · Norway (2) · Poland (2) · Spain (2)
Brandon Triplett, MD (3) · Mitchell Horwitz, MD (2) · Alan S Wayne, MD (1) · Ann Jakubowski, MD (1) · Arend von Stackelberg, MD (1) · David Snyder, PhD (1) · Diane George, MD (1) · Everett H Meyer, MD, PhD (1) · Everett Meyer (1) · Franco Locatelli, Professor (1) · Gregory Hale, M.D. (1) · Jeffrey S. Miller, MD (1) · Joanne Kurtzberg, MD (1)
PMID 22198152, PMID 23169518, PMID 23907766, PMID 24911148, PMID 29463563, PMID 30239252, PMID 30523748, PMID 31092732, PMID 31098682, PMID 32959985, PMID 38091578, PMID 39792934, PMID 41379293
2018 (1), 2025 (1), R01HL114591 (1)